FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080836582> ?p ?o ?g. }

• W2080836582 endingPage "279" @default.
• W2080836582 startingPage "270" @default.
• W2080836582 abstract "Introduction Sorafenib is the only drug approved by the Food and Drug Administration for metastatic hepatocellular carcinoma (HCC). Triptolide, a diterpene triepoxide, exhibits antineoplastic properties in multiple tumor cell types. In this study, we examined the effects of these agents and their combination on HCC in vitro and in vivo models. Methods HuH-7 and PLC/PRF/5 cells were treated with triptolide (50 nM), sorafenib (1.25 or 2.5 μM), or a combination of both. Cell viability assay (CCK-8), caspase 3&7 activation, and nuclear factor κB assays were performed. For in vivo studies, 40 mice were implanted with subcutaneous HuH7 tumors and divided into four treatment groups (n = 10); saline control, sorafenib 10 mg/kg PO daily (S), Minnelide (a prodrug of triptolide) 0.21 mg/kg intraperitoneally7 daily (M), and combination of both (C). Tumor volumes were assessed weekly. Results The combination of triptolide and sorafenib was superior to either drug alone in inducing apoptosis and decreasing viability, whereas triptolide alone was sufficient to decrease nuclear factor κB activity. After 2 weeks of treatment, tumor growth inhibition rates were S = 59%, M = 84%, and C = 93%, whereas tumor volumes in control animals increased by 9-fold. When crossed over to combination treatment, control mice tumor growth volumes plateaued over the following 4 weeks. Conclusion The combination of sorafenib and triptolide is superior to single drug treatment in increasing cell death and apoptosis in vitro. Combining sorafenib with Minnelide inhibited tumor growth with greater efficacy than single-agent treatments. Importantly, in vivo combination treatment allowed for using a lesser dose of sorafenib (10 mg/kg), which is less than 10% of currently prescribed dose for HCC patients. Therefore, combination treatment could have translational potential in the management of HCC." @default.
• W2080836582 created "2016-06-24" @default.
• W2080836582 creator A5013488451 @default.
• W2080836582 creator A5027451993 @default.
• W2080836582 creator A5029760021 @default.
• W2080836582 creator A5070041010 @default.
• W2080836582 creator A5072799975 @default.
• W2080836582 creator A5088154323 @default.
• W2080836582 creator A5088558334 @default.
• W2080836582 creator A5088574012 @default.
• W2080836582 date "2014-08-01" @default.
• W2080836582 modified "2023-09-27" @default.
• W2080836582 title "Sorafenib and triptolide as combination therapy for hepatocellular carcinoma" @default.
• W2080836582 cites W1533021978 @default.
• W2080836582 cites W1970060716 @default.
• W2080836582 cites W1971773437 @default.
• W2080836582 cites W1971837077 @default.
• W2080836582 cites W1988105205 @default.
• W2080836582 cites W2015588686 @default.
• W2080836582 cites W2020002352 @default.
• W2080836582 cites W2021937419 @default.
• W2080836582 cites W2023848967 @default.
• W2080836582 cites W2033140585 @default.
• W2080836582 cites W2037016917 @default.
• W2080836582 cites W2038713860 @default.
• W2080836582 cites W2050512142 @default.
• W2080836582 cites W2057265320 @default.
• W2080836582 cites W2065346431 @default.
• W2080836582 cites W2070396671 @default.
• W2080836582 cites W2070996506 @default.
• W2080836582 cites W2087980926 @default.
• W2080836582 cites W2111639514 @default.
• W2080836582 cites W2114994872 @default.
• W2080836582 cites W2115754856 @default.
• W2080836582 cites W2122083586 @default.
• W2080836582 cites W2123425686 @default.
• W2080836582 cites W2123877785 @default.
• W2080836582 cites W2134887638 @default.
• W2080836582 cites W2135636312 @default.
• W2080836582 cites W2140765540 @default.
• W2080836582 cites W2147748185 @default.
• W2080836582 cites W2155671268 @default.
• W2080836582 cites W2163685397 @default.
• W2080836582 cites W3021431521 @default.
• W2080836582 cites W4211105405 @default.
• W2080836582 doi "https://doi.org/10.1016/j.surg.2014.04.055" @default.
• W2080836582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24953273" @default.
• W2080836582 hasPublicationYear "2014" @default.
• W2080836582 type Work @default.
• W2080836582 sameAs 2080836582 @default.
• W2080836582 citedByCount "57" @default.
• W2080836582 countsByYear W20808365822014 @default.
• W2080836582 countsByYear W20808365822015 @default.
• W2080836582 countsByYear W20808365822016 @default.
• W2080836582 countsByYear W20808365822017 @default.
• W2080836582 countsByYear W20808365822018 @default.
• W2080836582 countsByYear W20808365822019 @default.
• W2080836582 countsByYear W20808365822020 @default.
• W2080836582 countsByYear W20808365822021 @default.
• W2080836582 countsByYear W20808365822022 @default.
• W2080836582 countsByYear W20808365822023 @default.
• W2080836582 crossrefType "journal-article" @default.
• W2080836582 hasAuthorship W2080836582A5013488451 @default.
• W2080836582 hasAuthorship W2080836582A5027451993 @default.
• W2080836582 hasAuthorship W2080836582A5029760021 @default.
• W2080836582 hasAuthorship W2080836582A5070041010 @default.
• W2080836582 hasAuthorship W2080836582A5072799975 @default.
• W2080836582 hasAuthorship W2080836582A5088154323 @default.
• W2080836582 hasAuthorship W2080836582A5088558334 @default.
• W2080836582 hasAuthorship W2080836582A5088574012 @default.
• W2080836582 hasConcept C126322002 @default.
• W2080836582 hasConcept C150903083 @default.
• W2080836582 hasConcept C190283241 @default.
• W2080836582 hasConcept C207001950 @default.
• W2080836582 hasConcept C2776999253 @default.
• W2080836582 hasConcept C2778019345 @default.
• W2080836582 hasConcept C2778695046 @default.
• W2080836582 hasConcept C2781164371 @default.
• W2080836582 hasConcept C55493867 @default.
• W2080836582 hasConcept C71924100 @default.
• W2080836582 hasConcept C86803240 @default.
• W2080836582 hasConcept C98274493 @default.
• W2080836582 hasConceptScore W2080836582C126322002 @default.
• W2080836582 hasConceptScore W2080836582C150903083 @default.
• W2080836582 hasConceptScore W2080836582C190283241 @default.
• W2080836582 hasConceptScore W2080836582C207001950 @default.
• W2080836582 hasConceptScore W2080836582C2776999253 @default.
• W2080836582 hasConceptScore W2080836582C2778019345 @default.
• W2080836582 hasConceptScore W2080836582C2778695046 @default.
• W2080836582 hasConceptScore W2080836582C2781164371 @default.
• W2080836582 hasConceptScore W2080836582C55493867 @default.
• W2080836582 hasConceptScore W2080836582C71924100 @default.
• W2080836582 hasConceptScore W2080836582C86803240 @default.
• W2080836582 hasConceptScore W2080836582C98274493 @default.
• W2080836582 hasIssue "2" @default.
• W2080836582 hasLocation W20808365821 @default.
• W2080836582 hasOpenAccess W2080836582 @default.
• W2080836582 hasPrimaryLocation W20808365821 @default.

• next